Transgelin Contributes to a Poor Response of Metastatic Renal Cell Carcinoma to Sunitinib Treatment

Transgelin Contributes to a Poor Response of Metastatic Renal Cell Carcinoma to Sunitinib Treatment

Renal cell carcinoma (RCC) represents about 2–3% of all cancers with over 400,000 new cases per year. Sunitinib, a vascular endothelial growth factor tyrosine kinase receptor inhibitor, has been used mainly for first-line treatment of metastatic clear-cell RCC with good or intermediate prognosis. Ho...

Full description

Bibliographic Details
Main Authors: Pavla Bouchalova, Jindrich Beranek, Petr Lapcik, David Potesil, Jan Podhorec, Alexandr Poprach, Pavel Bouchal
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Biomedicines
Subjects:
mccRCC
sunitinib
resistance
DIA-MS
transgelin
Online Access:https://www.mdpi.com/2227-9059/9/9/1145

Similar Items

Similar Items